"Roadmap for success in oncology"
 
SCRIP Executive Briefing, Vol 1 No 3, 2008
The worldwide oncology market is projected to outgrow the rest of the pharma industry, becoming the number one therapeutic class in revenue terms by 2011. So will oncology become pharma’s new “holy grail”?
By Dr Frederic Desdouits, Lionel Delaporte and Dr Stéphane Parnis

 

"Cornering the EU Market: the need for Creative Strategies"
 
EBR Spring 2008
When it comes to the accessibility of the EU pharmaceutical market, it is clear that a number of factors have changed in the past few years. Evolution or revolution?
By Alain J Gilbert and Mark Larkin

 

"Pharma Deals"
 
Pharmaceutical Executive, may 2008
Many say licensing is the new R&D. The thrid quarter of 2007 featured some pricey cherry-picking. Will the unions bear fruit? We've the intersting ones to watch.
By Daniel Teper

 

"Innovation takes the prize"
 
Pharmaceutical Executive, october 2007
A celebration of the first annual Prix Galien, by Daniel Teper

 

"Up or Out in Oncology" ­ Executive Summary only
 
Bionest Disease Area Review, November 2007
Stéphane Parnis, Guillaume Madec, Lionel Delaporte and Frédéric Desdouits produced the second edition of our annual review related to the outlook of the oncology market. As part of the report, the authors provide advice to bio-pharmaceutical companies on how to develop and sustain a profitable business in this attractive but risky domain.
To request the 78-page full report, please click here

 

Net Profit
 
EBR, autumn 2007
Bionest¹s Frédéric Desdouits and Catherine Pichereau compare methods of valuing biotech and find that public markets offer a means to value companies even with as little information as is available on their website.

 

Vaccines : Growth Boosters
 
Exane BNP Paribas Equity Research Report, June 2006
Alain Gilbert, Claude Allary and Frédéric Desdouits, in collaboration with
Exane BNP Paribas, anticipate the radical changes set to occur in the
vaccines industry and illustrate them with two case studies

 

Reaching Maturity – New Challenges for an Evolving Industry
 
VentureCapital Magazin, April 2006 (article in German)
Frédéric Desdouits and Christian Hein analyse the current state of the German biotech industry and its future challenges: the need to internationalize and to start commercializing its own products.

 

 Oncology Pipelines – Searching is not Finding
 
Exane BNP Paribas Equity Research Report, March 2006
Frédéric Desdouits and Stéphane Parnis, in collaboration with Exane BNP Paribas, have produced an in-depth study of the oncology sector, reviewing the past and forecasting future trends.

 

 Therapeutic Peptides Under the Spotlight
 
EBR, January 2006
Catherine Pichereau and Claude Allary explore the challenges, trends and opportunities within a sector receiving increasing attention.

 

 The European Giant Stirs from Slumber
 
Biotechnologies et Finances, December 2005
Frédéric Desdouits and Catherine Pichereau review the evolution of the financial landscape of the Biotech industry in 2005.

 

 Great Oaks from Little Acorns
 
Scrip Magazine, November 2005
Alain Gilbert, Mark Larkin, Vanessa Coudre and Xavier Paoli explain how big things can come from small beginnings with an EAP (Early Access Programme).

 

 The Unlikely European Biotech Poker Game
 
EBR, Summer 2005
Catherine Pichereau looks at the difficulties European biotech companies encounter raising public funds.

 

Vioxx: Lifting the Veil on the Dark Side of the Pharmaceutical Industry
 
EBR, Spring 2005
Catherine Pichereau examines the consequences of the Vioxx scandal.

 

Entry in Europe – Companies from Overseas Face Critical Issues
 
Biotechnology in Europe Today, Autumn 2004
Mark Larkin explores the issues faced by companies considering becoming players in the European market.

 

Risky Business
 
Scrip Magazine, September 2004
Alain Gilbert and Mark Larkin discuss how European Biotech companies can be sustainable in a risk-averse environment.

 

EU biotech: United we Stand, Divided we Fall
 
Scrip Magazine, July/August 2004
Claude Allary and Catherine Pichereau look at the results of a survey examining why there are so few biotech consolidations in Europe, and suggest ways to increase their number.

 

Local Brand Strategy is the Weakest Link
 
Scrip Magazine, December 2003
Lionel Delaporte, Loic Plantevin and Kate Parker explore why local brand strategic planning is becoming increasingly critical